Heterogeneous EGFR expression has been observed: approximately 10%–20% of cSCC patients exhibit low EGFR expression (IHC score 1+) or are negative in tumor tissues, potentially rendering them unresponsive to EGFR/CD3 bispecific antibodies (130). This evidence concerns the gene EGFR and neoplasm.